TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Buck Institute and Georgetown University are co-leading a four-year research consortium funded by an Advanced Research Projects Agency for Health award of up to $51.7 million. The team plans to combine experiments and computational modeling to study how intrinsically disordered proteins change under different cellular conditions, initially focusing on Alzheimer’s disease and Ewing sarcoma. The work aims to improve prediction and detection, but it has not yet produced a diagnostic or treatment.
The Buck Institute for Research on Aging and Georgetown University are co-leading a four-year research effort backed by an Advanced Research Projects Agency for Health (ARPA-H) award of up to $51.7 million to predict how disease-linked proteins change before they cause lasting cellular damage. The consortium, called Team SEEDS, will initially study proteins associated with Alzheimer’s disease and Ewing sarcoma, pairing computational predictions with laboratory experiments.
SEEDS stands for Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale. It brings together researchers from nine academic institutions and seven industry partners, combining expertise in protein science, artificial intelligence, computational modeling, cancer and neuroscience. Georgetown’s Priyanka Joshi, PhD, and the Buck Institute’s Chuankai (Kai) Zhou, PhD, co-lead the effort.
The team will investigate intrinsically disordered proteins (IDPs), which do not settle into one stable three-dimensional shape. Instead, they can take on different forms, with behavior influenced by cellular conditions such as acidity, molecular crowding, metals, metabolites and chemical modifications. The project will test how those surroundings affect protein behavior, rather than relying on computer models alone.
The researchers aim to connect a protein’s sequence and environment to the range of shapes and behaviors it adopts, then identify shifts associated with disease. The award is for work intended to develop the scientific basis for new detection approaches and, eventually, interventions. The source report does not describe a completed diagnostic, treatment or clinical trial.
Why Early Protein Changes Matter
Protein misfolding and aggregation are associated with Alzheimer’s disease, ALS, some cancers and other chronic or degenerative conditions. If researchers can identify harmful changes before proteins clump together or cause irreversible cellular injury, that knowledge could help guide earlier detection and future treatment research. Those are goals of the project, not outcomes established by the award announcement.
Many IDPs are difficult to target with conventional drug-development approaches because they lack the stable shapes and binding pockets that many medicines are designed to fit. A method that better predicts how these flexible proteins behave could help researchers investigate targets that have been considered difficult to drug. Whether SEEDS will produce practical diagnostic tests or therapies, and how long that might take, remains unknown.
As an affiliate, we earn on qualifying purchases.
The BIOGAMI Research Program
SEEDS is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program, which focuses on early stages of protein dysfunction, before misfolding and aggregation cause lasting cell damage. BIOGAMI uses “molecular grammar” as a way to describe the rules that may connect protein sequence and cellular conditions to protein behavior. ARPA-H Program Manager Shannon Greene, PhD, leads the program.
Researchers can capture snapshots of proteins, but the source report says they cannot yet reliably predict how IDPs will behave as cellular conditions change or when a shift becomes harmful. Structural prediction tools such as AlphaFold have benefited from extensive accumulated data on protein structures. Zhou said there is less comparable structural information for IDPs, complicating efforts to build predictive models for them. SEEDS plans to address that gap by collecting data at scale and testing model predictions experimentally.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
As an affiliate, we earn on qualifying purchases.
Questions the Project Must Answer
The announcement does not specify which individual proteins or cellular conditions will be prioritized, how the team will measure success, or when any candidate diagnostic or treatment might emerge. It also does not report validated predictions, human studies or evidence that a proposed intervention can prevent disease-related damage.
The award is described as up to $51.7 million; the source does not provide a payment schedule or explain what conditions determine the final amount. The research is expected to run for four years, but milestones and interim findings were not included in the report.
As an affiliate, we earn on qualifying purchases.
Four Years of Model Testing
Over the four-year effort, the consortium plans to build a platform for predicting IDP behavior from sequence and cellular surroundings, then compare those predictions with experimental measurements. Its initial disease focus is Alzheimer’s disease and Ewing sarcoma. The research design calls for experiments to test and refine the computational models under differing conditions.
Future updates would need to show whether the approach can predict protein behavior reproducibly and identify changes relevant to disease. The award announcement does not set a date for results or specify when any findings might be ready for clinical evaluation.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is leading the protein research effort?
The effort is co-led by Georgetown University’s Priyanka Joshi and the Buck Institute’s Chuankai (Kai) Zhou. Team SEEDS includes researchers from nine academic institutions and seven industry partners.
How much funding did the team receive?
ARPA-H awarded the consortium up to $51.7 million for a four-year effort. The source report does not give a disbursement schedule or the final amount to be paid.
What proteins will the researchers study?
The team will study intrinsically disordered proteins, which can adopt multiple shapes rather than one stable structure. Its initial disease focus is Alzheimer’s disease and Ewing sarcoma.
Does the project already offer a test or treatment?
No. The announcement describes research intended to improve prediction and potentially support future detection and treatment approaches. It does not report an available diagnostic, a new therapy or clinical evidence.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
